Aziyo Biologics Inc. (AZYO) News
Filter AZYO News Items
AZYO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AZYO News Highlights
- For AZYO, its 30 day story count is now at 4.
- Over the past 16 days, the trend for AZYO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about AZYO are MD and RM.
Latest AZYO News From Around the Web
Below are the latest news stories about AZIYO BIOLOGICS INC that investors may wish to consider to help them evaluate AZYO as an investment opportunity.
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative ProceduresCase provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced the publication of a case report highlighting results that dem |
Aziyo Biologics, Inc. (NASDAQ:AZYO) Q2 2023 Earnings Call TranscriptAziyo Biologics, Inc. (NASDAQ:AZYO) Q2 2023 Earnings Call Transcript August 20, 2023 Operator: Good day, ladies and gentlemen. Welcome to the Aziyo Biologics’ Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference call is being recorded. I would now like to hand the conference over to Matt Steinberg of […] |
Q2 2023 Aziyo Biologics Inc Earnings CallQ2 2023 Aziyo Biologics Inc Earnings Call |
Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix CompanyNegotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today |
Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pa |
CDC, health agencies investigate amid Aziyo Biologics' voluntary recall of bone repair product following TB infectionsThe CDC said it's working with seven state health departments to investigate potential tuberculosis cases after Aziyo Biologics Inc. (NASDAQ: AZYO) announced a voluntary recall and halted shipments of one of its bone repair products "out of an abundance of caution." Aziyo — one of the region's largest bioscience players — offers viable bone matrix products, which are made from human tissue and used in orthopedic and spinal procedures, among many other medical devices. The Silver Spring company said earlier this month that two patients treated with a viable bone matrix product, both made from the same donor lot, developed tuberculosis after spinal surgeries. |
SWK Holdings Highlights Recent Achievements and Provides Portfolio UpdateSWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower partners. |
Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix ProductsSILVER SPRING, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced a voluntary recall of its viable bone matrix products, which are bone repair products made from human tissue that are used primarily in orthopedic and spinal procedures. Notice of the voluntary recall was issued to centers after the Company learned o |
3 Micro-Cap Stocks to Buy Now for Gigantic Growth PotentialThe smallest stocks have been trailing their larger counterparts. |
Aziyo Biologics Presents Clinical Data On CanGaroo Biologic Envelope In Patients Receiving Cardiac Implantable Electronic DevicesAziyo Biologics Inc (NASDAQ: AZYO) announced that data from the HEAL Study will be presented at the Heart Rhythm Society this Sunday. HEAL is a national multi-center study evaluating patients who previously underwent implantation of a cardiac implantable electronic device (CIED) with either an Aziyo CanGaroo Envelope, Medtronic Plc's (NYSE: MDT) Tyrx non-biologic envelope, or no envelope, and are returning for a revision procedure at least four months after initial placement. The CanGaroo Envelo |